BR0311826A - Inibidores da interação gpib-vwf, sua preparação e uso - Google Patents

Inibidores da interação gpib-vwf, sua preparação e uso

Info

Publication number
BR0311826A
BR0311826A BR0311826-6A BR0311826A BR0311826A BR 0311826 A BR0311826 A BR 0311826A BR 0311826 A BR0311826 A BR 0311826A BR 0311826 A BR0311826 A BR 0311826A
Authority
BR
Brazil
Prior art keywords
gpib
compounds
preparation
formula
vwf
Prior art date
Application number
BR0311826-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Otmar Klingler
Melitta Just
Kuniya Sakurai
Naoyuki Fukuchi
Original Assignee
Ajinomoto Co Inc Pharmaceutica
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc Pharmaceutica, Aventis Pharma Gmbh filed Critical Ajinomoto Co Inc Pharmaceutica
Publication of BR0311826A publication Critical patent/BR0311826A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
BR0311826-6A 2002-06-06 2003-06-06 Inibidores da interação gpib-vwf, sua preparação e uso BR0311826A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02012590A EP1369420A1 (en) 2002-06-06 2002-06-06 Inhibitors of the GPib - vWF interaction
PCT/EP2003/005955 WO2003104221A1 (en) 2002-06-06 2003-06-06 Inhibitors of the gpib -vwf interaction, their preparation and use

Publications (1)

Publication Number Publication Date
BR0311826A true BR0311826A (pt) 2005-03-29

Family

ID=29433122

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311826-6A BR0311826A (pt) 2002-06-06 2003-06-06 Inibidores da interação gpib-vwf, sua preparação e uso

Country Status (9)

Country Link
EP (2) EP1369420A1 (enExample)
JP (1) JP4455326B2 (enExample)
AT (1) ATE353082T1 (enExample)
AU (1) AU2003274686A1 (enExample)
BR (1) BR0311826A (enExample)
CA (1) CA2488193A1 (enExample)
DE (1) DE60311578T2 (enExample)
MX (1) MXPA04011408A (enExample)
WO (1) WO2003104221A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004080950A1 (en) * 2003-03-14 2004-09-23 H. Lundbeck A/S Substituted aniline derivatives
AR043507A1 (es) * 2003-03-14 2005-08-03 Lundbeck & Co As H Derivados de anilina sustituidos y composiciones farmaceuticas
US7932272B2 (en) 2003-09-30 2011-04-26 Eisai R&D Management Co., Ltd. Antifungal agent containing heterocyclic compound
WO2006016548A1 (ja) * 2004-08-09 2006-02-16 Eisai R & D Management Co., Ltd. ヘテロ環化合物を含有する新規な抗マラリア剤
WO2006106711A1 (ja) 2005-03-30 2006-10-12 Eisai R & D Management Co., Ltd. ピリジン誘導体を含有する抗真菌剤
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
WO2008035726A1 (en) 2006-09-21 2008-03-27 Eisai R & D Management Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
CN101622251B (zh) 2007-04-27 2012-07-04 卫材R&D管理有限公司 杂环取代吡啶衍生物的盐或其结晶
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
JP2010531358A (ja) 2007-06-27 2010-09-24 メルク・シャープ・エンド・ドーム・コーポレイション ヒストン脱アセチル化酵素阻害剤としてのピリジル及びピリミジニル誘導体
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
US8188119B2 (en) 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
BR112013008898A2 (pt) * 2010-10-11 2016-06-28 Auckland Uniservices Limited benzamidas substituídas e seus usos
EP2838534A4 (en) 2012-04-12 2015-11-11 Univ Leland Stanford Junior SUBSTITUTED BENZAMIDES AND USES THEREOF
JP7881153B2 (ja) * 2021-11-26 2026-06-29 学校法人東海大学 フォンヴィルブランド因子と血小板との結合を阻害するための医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW301607B (enExample) * 1993-03-09 1997-04-01 Takeda Pharm Industry Co Ltd
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
AU5812498A (en) * 1996-12-20 1998-07-17 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity

Also Published As

Publication number Publication date
EP1369420A1 (en) 2003-12-10
AU2003274686A1 (en) 2003-12-22
EP1509516A1 (en) 2005-03-02
DE60311578T2 (de) 2007-11-15
JP4455326B2 (ja) 2010-04-21
DE60311578D1 (de) 2007-03-22
ATE353082T1 (de) 2007-02-15
EP1509516B1 (en) 2007-01-31
JP2005528459A (ja) 2005-09-22
CA2488193A1 (en) 2003-12-18
AU2003274686A8 (en) 2003-12-22
MXPA04011408A (es) 2005-09-30
WO2003104221A1 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
AU2003274686A8 (en) Inhibitors of the gpib -vwf interaction, their preparation and use
CY1112274T1 (el) Νεοι ολιγοσακχαριτες, η παρασκευh τους και οι φαρμακευτικες συνθεσεις οι οποιες τους περιεχουν
BR0016396A (pt) Novos antagonistas do receptor p2x7 para uso no tratamento de doenças inflamatórias, imunes ou cardiovasculares
EE03969B1 (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
BR9808998A (pt) Imidazóis substituìdos úteis no tratamento de doenças inflamatórias
FI902970A0 (fi) Imidazolylalkensyror.
EA200500595A1 (ru) Новые алкиновые соединения, обладающие антагонистическим в отношении мсн действием, и содержащие эти соединения лекарственные средства
CY1107871T1 (el) Παραγωγα πυριμιδινης και η χρηση τους ως ρυθμιστων cb2
CY1110177T1 (el) Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
NO20026064D0 (no) Nye forbindelser
ATE427936T1 (de) Substituierte piperidin-verbindungen als modulatoren der chemokine receptor aktivitat
SE8804629D0 (sv) New therapeutically active compounds
BRPI0108395B8 (pt) derivados de pirrolopirimidinona, processos de preparação e uso
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
CY1108190T1 (el) Ανασυνδυασμενος υποδοχεας κολλαγονου αιμοπεταλιων της γλυκοπρωτεϊνης vi και η φαρμακευτικη του χρηση
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
NO904666L (no) Kondenserte polycykliske forbindelser, fremgangsmaater forfremstilling derav og anvendelse som paf-antagonister, antihistaminer og/eller antiinflammatoriske midler.
BR0208741A (pt) Derivados de piperidina
BG101867A (bg) Бензотиазиндиоксиди като антагонисти на ендотелин
SE0101038D0 (sv) Novel compounds
ATE309339T1 (de) Thrombomodulin analoga und ihre pharmazeutische verwendung
ATE244712T1 (de) Piperazino-derivative als neurokininantagonisten
UA48958C2 (uk) 9-o-оксимові похідні еритроміцину а та фармацевтична композиція на їх основі

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010.